Repligen Corporation filed a Form 425 on August 3, 2026, relating to its proposed acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS) under a Merger Agreement dated July 21, 2026, consisting of a transcript of a video message from Repligen's President and CEO to BioLife employees.

Key Highlights

  • Deal terms: Each outstanding share of BioLife common stock would receive $11.25 in cash and 0.1442 shares of Repligen common stock, per the Merger Agreement.
  • Agreement date: The Merger Agreement was signed on July 21, 2026, among Repligen, two wholly owned subsidiaries, and BioLife Solutions.
  • Expected close: According to the filing, regulatory and shareholder approvals are still required, with closing expected in the fourth quarter of 2026.
  • Separate operations: The filing states that until closing, Repligen and BioLife "will continue to operate as two separate, independent companies."
  • Repligen profile: The CEO described Repligen as founded in 1981, headquartered in Waltham, Massachusetts, with a global team of approximately 2,000 people across North America, Europe, and Asia.
  • Subject company platform: The CEO noted that BioLife's CryoStor platform "supports commercially approved cell therapies and the majority of US cell based therapy trials."

Repligen CEO Addresses BioLife Employees Following Merger Announcement

The Form 425, filed by Repligen Corporation and relating to subject company BioLife Solutions, Inc. (NASDAQ: BLFS), contains a transcript of a video message recorded by Olivier Loeillot, President and Chief Executive Officer of Repligen, and sent to BioLife on August 3, 2026. The filing was made pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934. Repligen's SEC File No. is listed as 001-36362.

In the transcript, Loeillot described Repligen as "a bioprocessing company" that builds "tools and technologies that help our customers make biologic drugs faster, with higher yield and with better quality." He stated the company's mission as "to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide." He noted that he has spent 30 years in the industry and that the company has grown through both innovation and acquisitions of other companies.

Regarding the transaction status, Loeillot told BioLife employees: "The transaction still needs regulatory and shareholder approvals, and we expect to close later this year in the fourth quarter." He also noted that the initial public announcement had occurred on July 22, 2026, and described it as "a very important first step, but it is just a first step." The filing contains forward-looking statements, which Repligen and BioLife identified as subject to risks and uncertainties, including the possibility that required approvals may not be obtained, that anticipated benefits may not be realized, and other factors detailed in the filing's cautionary language.

What Was Disclosed

Repligen filed a Form 425 containing a CEO video transcript addressed to BioLife Solutions employees, confirming the July 21, 2026 Merger Agreement, the per-share consideration of $11.25 cash plus 0.1442 Repligen shares, and a targeted fourth-quarter 2026 close pending approvals.